Caldwell Cassady & Curry Helps Acantha Win $8.2 Million Patent Infringement Verdict Against Medical Device Giant DePuy Synthes

GREEN BAY, Wisc., Aug. 23, 2018 /PRNewswire/ — The Dallas-based intellectual property and business litigation law firm Caldwell Cassady & Curry has won an $8.2 million patent infringement verdict for Acantha LLC against medical device manufacturer DePuy Synthes, a subsidiary of health care giant Johnson & Johnson (NYSE : JNJ ).

A jury of five women and three men issued the unanimous verdict on Aug. 21, 2018, following seven days of trial before the Hon. Chief Judge William C. Griesbach in the U.S. District Court for the Eastern District of Wisconsin in Green Bay. Jurors reached their verdict following five hours of deliberations.

DePuy Synthes was sued in 2015 based on claims that it had infringed an Acantha patent, U.S. Patent No. RE43,008 (‘008 patent), which covers an orthopedic implant assembly used to join bone segments. Acantha’s ‘008 patent was originally issued in 2001 before being reissued in 2011 by the U.S. Patent and Trademark Office.

The Caldwell Cassady & Curry trial team representing Acantha at trial included Brad CaldwellAustin CurryChris StewartJohn Summers and Seth Reich.

Jurors heard evidence that David Talaber, one of the two co-inventors of the ‘008 patent, informed DePuy Synthes’s predecessors about the patent in writing and by phone the year after it was issued.

Mr. Talaber’s co-inventor, Dr. James Lloyd, later traveled to DePuy’s Massachusetts headquarters in 2006 to explain how Acantha’s patent could help with problems DePuy experienced with its implant devices. The DePuy companies never licensed the patent.

Acantha asserted that DePuy Synthes subsequently infringed the ‘008 patent in a series of spine implant devices, including the Zero-P VA System and the Vectra, Vectra-T, and Vectra-One products.

The Green Bay jury found that the DePuy companies willfully infringed Acantha’s patent, awarding $8.2 million in actual damages. The case is Acantha LLC v. DePuy Synthes Sales Inc., et al., No. 1:15-CV-01257.

Caldwell Cassady & Curry represents companies and individuals in high-stakes civil litigation, including patent infringement cases, trade secrets claims, fiduciary duty cases, class actions, and disputes involving company founders. The firm has tried and won some of the nation’s top verdicts against the largest companies in the world. For more information, visit www.caldwellcc.com.

For more information, contact Bruce Vincent at 214-763-6226 or bruce.vincent@musecommunicationsllc.com.

SOURCE Caldwell Cassady & Curry

Related Links

http://www.caldwellcc.com

First Silony VERTICALE Open Procedures Performed in United States

MIAMIAug. 22, 2018 /PRNewswire/ — Silony Medical is pleased to announce that it has performed its first lumbar cases in the US. Silony offers tailor-made sets of sterile pedicle screws ranging from 4.5 to 10.2mm width in 25 to 100mm lengths. One of the initial users, Dr. Mehta at St. Mary Medical Center in Hobart IN, was very satisfied with the quality, intuition and efficiency of the instrument sets and their multi-functionality given Silony’s clinically driven approach. Furthermore, the hospital´s operating room staff provided very positive feedback in regards to simplicity, handling, and quality of Silony´s products. More than 55,000 screws have been implanted in countries like Germany, UK, AustriaItaly and the Netherlands since late 2013. Silony is a fast growing family-owned spine company, developing and producing all its high-quality products in Germany. Silony is currently present in more than 10 countries and is now successfully entering the US market. All Silony products are developed in close cooperation with an international board of surgeons and other hospital experts.

VERTICALE is a posterior double rod fixation system for stabilizing the thoracic and lumbar spine. The system was developed in close cooperation with experienced and qualified spinal surgeons as well as theatre and sterilization staff in surgical environments. As a result, VERTICALE is a well-designed, modular and versatile fixation system.

The VERTICALE system is made up of polyaxial, monoaxial, uniplanar and iliac screws that are available as short head and long head screws (reduction screws). This range of pedicle screws, in either solid or cannulated and fenestrated versions, combined with 5.5-mm titanium or cobalt chromium rods means that the VERTICALE system is suitable for a wide range of indications. Degenerative spinal diseases can be stabilized in a controlled manner and deformities can be comfortably corrected.

Contact Information

E-mail: 

info.usa@silony-medical.com

Phone number: 

305 916 0016

Website: 

http://us.silony-medical.com/

 

Verticale Open (PRNewsfoto/Silony Medical)

Centinel Spine Announces Initial Cases with FLX™ Platform of 3D Printed All-Titanium Interbodies

NEW YORKAug. 23, 2018 /PRNewswire/ — Centinel Spine, LLC announced today that it has completed initial cases with three different implant portfolios within their FLX™ Platform of Integrated Interbody™ and non-integrated interbody fusion devices.  Centinel Spine is the largest privately-held spine company focused on anterior column reconstruction.

FLX devices are 3D-printed, all-titanium implants which feature a combination of solid and porous radiolucent sections designed to reduce mechanical stiffness and improve visibility, as compared to solid titanium implants.  The devices also feature a proprietary FUSE-THRU™ trabecular scaffold, designed to allow for bony in-growth and on-growth throughout the implant.  Centinel Spine received FDA-clearance for multiple cervical and lumbar interbody fusion device families in May of this year.

“FLX offers me another great material choice to add to my fusion armamentarium,” says Dr. Jason Garber, a Neurosurgeon with Las Vegas Neurosurgical Institute, implanting STALIF C FLX™ Cervical Integrated Interbody and STALIF M FLX™ Lumbar Integrated Interbody devices. “With STALIF® implants made from PEEK, titanium-surfaced PEEK, and now 3D-printed titanium, I have the unique opportunity to provide my patients with optimal care options for their individual and specific needs.”

STALIF FLX Integrated Interbody devices offer a unique advantage over other all-titanium implants—as they are indicated for use at one or two contiguous levels with both autograft and/or allogenic bone graft.

Dr. Stelios Koutsoumbelis, Chief of Division of Orthopedic Surgery at South Nassau Communities Hospital, performing the first ACTILIF C FLX Cervical Interbody implantation comments, “The FLX implant offers an open bone graft window optimizing graft volume and allowing bone growth throughout the trabecular matrix structure.  The open configuration also allows for CT visualization post-operatively to assess fusion.”

“The initial implantations of these FLX products represent a significant milestone in the evolution of our interbody technologies and advanced material platforms.  Our FLX products merge the proven benefits of the STALIF design with a truly novel, all-titanium lattice technology.  This provides surgeons the flexibility to use multiple implant material options through a single set of instruments to address each patient’s unique pathology,” says Centinel Spine Chairman & CEO, John Viscogliosi.

Centinel Spine—the pioneer of the No-Profile®, Integrated Interbody—has a 30-year global clinical history of success behind these devices for the treatment of degenerative disc disease.  The FDA clearance of the FLX platform is the next step in the evolution of Centinel Spine executing on its mission to become the worldwide leading spine company, addressing spinal disease anteriorly with the widest breadth and depth of technology platforms.

About Centinel Spine, LLC.

Centinel Spine, LLC is a privately-held spinal device company leading the development and commercialization of the No-Profile, Integrated Interbody fusion technologies. The company recently acquired the prodisc® Total Disc Replacement portfolio, an extensive cervical and lumbar disc replacement platform with the longest history of global clinical use.  For more information on Centinel Spine products and technologies, please visit the company’s website at www.CentinelSpine.com.

The company began operations in August 2008, through the merger-acquisition of two pioneering medical device companies: Raymedica, LLC and Surgicraft, LTD. Today, Centinel Spine still embraces the pioneering culture developed at both originating companies and continues its corporate mission of becoming the leading anterior column reconstruction spine franchise—providing elegantly simple implants and instruments that are tissue-sparing and generate superior clinical outcomes.

Centinel Spine derived its name from the “Sentinel Sign”, the radiographic confirmation of a successful fusion anterior to the interbody device.

For more information, please contact:

Varun Gandhi

SVP, Corporate Finance & Strategic Planning, Centinel Spine, LLC

900 Airport Road, Suite 3B

West Chester, PA 19380

Phone: 484-887-8871

Email: v.gandhi@centinelspine.com

Wendy F. DiCicco

Chief Operating and Chief Financial Officer, Centinel Spine, LLC

900 Airport Road, Suite 3B

West Chester, PA 19380

Phone: 484-887-8837

Email: w.dicicco@centinelspine.com

SOURCE Centinel Spine, LLC

(PRNewsfoto/Centinel Spine, LLC)

Related Links

http://www.CentinelSpine.com

Stimwave Names Industry Veterans Paul LaViolette and Jeffrey Goldberg to Board of Directors

August 23, 2018

POMPANO BEACH, Fla.–(BUSINESS WIRE)–Stimwave LLC, a medical device manufacturer and independent research institute headquartered in South Florida, announced today that Paul LaViolette, managing partner and chief operating officer of SV Health Investors and former COO of Boston Scientific, and Jeff Goldberg, former president of Al Mann’s medical-technology incubator, joined Stimwave’s Board of Directors.

“Paul is an inspirational thought leader who has helped grow companies who were disruptive in health care into multi-billion dollar enterprises, while improving the lives of millions,” said Stimwave Chairman and CEO of Laura Tyler Perryman. “He will be an outstanding addition to our board.”

LaViolette built and ran medical device businesses for 29 years, and he was chief operating officer at Boston Scientific (BSC). During his tenure, the company grew revenue over 20 times. He integrated two dozen acquisitions and led extensive product development, manufacturing and worldwide commercial organizations.

“It’s an honor and a privilege to come aboard with Stimwave as it deploys its innovative technology to market,” said LaViolette. “Medical devices focused on increased access, minimal invasiveness and state of the art technology are the future of health care, and Stimwave is well positioned to expand the neuromodulation market.”

“Jeff Goldberg served a critical role within Al Mann’s enterprises for many years, and Stimwave holds the same principles of creating a technology platform that can benefit patients’ lives, while increasing the market considerably by reimagining how we deliver neuromodulation,” said Perryman. “Familiarity with industry disruptor products such as Stimwave will be invaluable to our future growth plans as we continue to transform our business at an accelerated pace.”

Goldberg has been an executive and advisor in the health care industry for over 25 years. Recently, he served as chair of the board of Angiotech Pharmaceuticals and Physiotherapy Associates and is now serving as chair of the board of 21st Century Oncology, LifeCare Health Partners, Corizon Health, and M*Modal.

“The opportunity to treat pain without implanting a large battery, like what Laura and the Stimwave team are offering patients and their physicians, represents the same type of dramatic innovation that characterized Al Mann’s most successful companies,” Goldberg said. “I am honored to work with as creative and dynamic a leader with Laura and look forward to our journey together.”

Stimwave’s devices are the premier wireless stimulators, using Wireless Pain Relief® technology that allows them to be 95 percent smaller than any other neuromodulation device on the market. These devices treat back and leg pain, as well as treatment for shoulder pain, wrist and elbow pain, knee pain, hip pain and more.

About Stimwave LLC

Stimwave LLC is a privately held medical device company engaged in the development, manufacturing, and commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective pain management solution that is easily incorporated into their daily lives. Stimwave’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of pain management. www.stimwave.com

Contacts

Glodow Nead Communications
Lori Puccinelli Stern, Rosemary O’Brien and Sarah Rodgers, 415-394-6500
StimwavePR@GlodowNead.com

Osseus Fusion Systems’ new family of 3D printed titanium spine implants receives FDA approval

by  / 22 August 2018

A Texan medical device company has received FDA approval for five new spinal implants 3D printed in titanium.

The family of five FDA 510(k)-cleared lumbar interbody fusion devices is being brought to market by Osseus Fusion Systems under the brand name, Aries. Osseus has been working to develop advanced technology products to enable minimally invasive surgery since it was founded in 2012. In doing so, the company has developed PL3XUS, its proprietary 3D printing technology which uses powder bed fusion to build parts in titanium.

Aries devices boast 80% porosity, increased bone packability and low stiffness, per Osseus, and are manufactured in 30-micron layers before being sintered. A rigorous post-processing phase then optimises the devices ready for clinical use.

The implants are designed to help surgeons ease back pain, and are said to help with faster healing, improved bone growth and enhanced radiovisibility. They represent the first FDA-cleared 3D printed implants Osseus has developed, and double the volume of the company’s portfolio. Osseus says Aries is the first range of many 3D printed products it is working on, and with more to come, the company believes it now has an edge over its competitors.

 

READ THE REST HERE

Photos: Osseus Fusion Systems / TCT Magazine

Promising ACL surgery outcomes for aging athletes

ROSEMONT, Ill.Aug. 21, 2018 /PRNewswire/ — One of the most common knee injuries is an anterior cruciate ligament (ACL) sprain or tear, and doctors are seeing a greater number of older athletes end up in their offices with the injury. An estimated 200,000 ACL-related injuries occur annually in the United States.

Some patients choose to undergo surgical reconstruction of the ACL while others opt for non-surgical intervention. A new review article published in the August 15th issue of the Journal of the American Academy of Orthopaedic Surgeons (JAAOS) discusses surgical and non-surgical treatment options for patients over the age 40 with ACL injuries and proposes shared decision-making about care between patients and doctors.

“The benefits of staying active throughout your life greatly outweigh the risks,” emphasized lead study author and orthopaedic surgeon Matthew Salzler, MD. “ACL tears are an unfortunate but treatable injury that can occur, especially in sports that require sudden twisting and pivoting movements.”

Aging ACLs have a reduced potential to heal and a lower capacity to bear significant strain, as demonstrated in one study highlighted in the review article that compared rats injected with younger and older human ACL-derived cells. Older ACLs may also show greater degeneration.

The review article authors highlight that deciding between surgical and non-surgical treatment options depends on a patient’s activity level and should be a part of a doctor’s initial evaluation when treating patients for an ACL injury. The patient’s history of knee injuries and functional needs should be considered.

According to the article patients of all ages benefit from the rest, ice, compression and elevation (RICE) approach; therefore, this should be the initial management for ACL injuries. This helps reduce pain and swelling, and protects the knee from additional injury. In addition, early physical therapy may help return range of motion and knee stability.

The review article also highlights that the “rule of thirds” has been used for over 25 years to describe different types of patients. They may be classified as:

  • Copers: Able to resume all of their previous activity without any issues for at least one year after the injury.
  • Adapters: Modify or reduce activity after their injury.
  • Non-copers: Require ACL reconstructive surgery because they can’t get through everyday tasks.

The authors explained that though this pattern is not evidence-based, the concepts are relevant when treating patients over 40 as they’re more likely than younger patients to modify their activity over opting for surgical reconstruction.

The article states that the ideal candidates for reconstructive surgery are generally patients who haven’t shown enough improvement with physical therapy alone, want to participate in sports that require sudden pivoting or cutting – like basketball or skiing – and don’t have extensive degenerative changes.

In two systematic reviews of older patients who underwent ACL reconstruction, improvements and positive outcomes were found in knee stability and patient satisfaction. The Swedish National Anterior Cruciate Ligament Register also reported that while older patients had worse knee injury and osteoarthritis scores before surgery than younger patients, their scores after surgery were markedly better, and they showed the greatest improvement one, two, and five years after surgery.

“The outcomes of ACL reconstruction surgeries in patients over 40 are as good as – if not better than – those in younger patients,” says Dr. Salzler.

For patients leaning towards avoiding surgery, the study authors point out that there is conflicting data on the outcomes of nonsurgical treatment in those older than 40. One study of patients with ACL injuries aged 40 to 59 years that did not have surgery had worse outcomes than those that underwent reconstruction. However, in a separate study of Alpine skiers, those treated without surgery fared better than surgical patients.

“As with younger patients, an insufficient or torn ACL is likely to lead to an increased risk of knee instability, meniscal tears, and arthritis,” Dr. Salzler explains. “Whether a patient undergoes surgery or attempts non-operative management of an ACL tear requires a discussion with their orthopaedist.”

The full study is available at: http://bit.ly/2mq18yI

More information about the AAOS and JAAOS 

Follow the AAOS on FacebookTwitter and Instagram 

Follow the conversation about JAAOS on Twitter

Disclosures 

From Department of Orthopaedics, Tufts Medical Center, Boston, MA (Dr. Salzler), the Department of Orthopedics, University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO (Dr. Chang), and Boston Sports and Shoulder Center, New England Baptist HospitalWaltham, MA (Dr. Richmond). Dr. Salzler or an immediate family member is a board member or committee member of the American Orthopaedic Society for Sports Medicine. Dr. Richmond or an immediate family member serves as a paid consultant to Histogenics, Mitek, and Visgo Therapeutics; has received royalties and financial or material support from Springer and Wolters Kluwer Health–Lippincott Williams & Wilkins; and is a board member or committee member of the Arthroscopy Association of North America and Eastern Orthopaedic Education Foundation. Neither Dr. Chang nor any immediate family member has received anything of value from or has stock or stock options held in a commercial company or institution related directly or indirectly to the subject of this article. J Am Acad Orthop Surg 2018; 0:1-9 DOI: 10.5435/JAAOS-D-16-00730 Copyright 2018 by the American Academy of Orthopaedic Surgeons.

SOURCE American Academy of Orthopaedic Surgeons

Related Links

http://www.aaos.org

EOS imaging Achieves Its 100th Installation in the United States

August 21, 2018

PARIS–(BUSINESS WIRE)–Regulatory News:

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 – EOSI – Eligible PEA – PME), the pioneer of 2D/3D imaging and data solutions for orthopedics, today announced that the Methodist Dallas Medical Center installed an EOS® system for low-dose, 2D/3D imaging of adult and pediatric patients. The installation marks the 100th system installed in the United States and the 10th system in Texas.

Methodist Dallas Medical Center is part of the Methodist Health System that operates 10 hospitals in Texas and more than two dozen Methodist Family Health Centers and Medical Groups. The Methodist Dallas Medical Center has developed a comprehensive Neurological and Spine program with surgical staff specializing in back pain, tumors, stroke conditions, spinal disorders and injuries as well as other neurological conditions.

Achieving the 100th EOS® installation in the U.S. and 10th in the state of Texas represent great milestones for our Company that reflect the adoption of the EOS technology as a standard of care in all orthopedic points of care, including the large and high growth community hospitals and private practices market,” said Marie Meynadier, CEO. “Addressing the needs of these care providers in the U.S. has been an important part of our commercial strategy in the last year, and we are happy to see that our investments are prompting an acceleration of the EOS® adoption. Our dynamics in the U.S., our largest and fastest growing market, have reached an excellent pace and together with our momentum in all markets provide confidence in our growth.”

About EOS imaging

EOS imaging designs, develops and markets EOS®, a major innovative medical imaging solution dedicated to osteo-articular pathologies and orthopedics combining equipment and services and targeting a $2B per year market opportunity. EOS imaging is currently present in 31 countries, including the United States under FDA agreement, Japan, China and the European Union under CE labelling, through the over 250 installed EOS® platforms representing around one million patient exams every year. Revenues were €37.1M in 2017, e.g. a +32% CAGR over 2012-2017.

For more information, please visit www.eos-imaging.com.

EOS imaging has been selected to integrate the EnterNext © PEA – PME 150 index, composed of 150 French, listed companies on the Euronext markets in Paris.

EOS imaging is listed on Compartment C of Euronext Paris
ISIN: FR0011191766 – Ticker: EOSI

Contacts

EOS imaging
Marie Meynadier
CEO
Ph: +33 (0)1 55 25 60 60
investors@eos-imaging.com
or
Press Relations (US)
Kirsten Thomas
The Ruth Group
Ph: 508-280-6592
kthomas@theruthgroup.com
or
Investor Relations (US)
Matt Picciano / Emma Poalillo
The Ruth Group
Ph: 646-536-7008 / 7024
EOS-imagingIR@theruthgroup.com

Amedica Announces Successful Completion of First Valeo® C+CSC with Lumen Interbody Fusion Surgery

SALT LAKE CITY, Aug. 21, 2018 (GLOBE NEWSWIRE) — Amedica Corporation (NASDAQ: AMDA), an innovative biomaterial company that develops and commercializes silicon nitride for biomedical applications, is pleased to announce the successful completion of the first spine fusion surgery using the Valeo C+CSC with Lumen Interbody Fusion Device.

The first surgery was performed by Dr. Tarek Elalayli of Nashville, TN. “The implant, consisting of a novel combination of solid and porous silicon nitride, is well-designed, and the surgical implantation was straight forward. The benefits of this new device include the potential for bone in-growth as well as on-growth, while a central lumen gives the surgeon flexibility to add bone graft, if needed. The device and underlying technology are a step toward spine fusion without the need for bone graft additives; with the advantages of good radiographic visualization, and inherent antibacterial properties of silicon nitride. No other spinal fusion implant combines all these properties.” said Dr. Elalayli.

The Valeo C+CsC with Lumen is Amedica’s newest spinal implant that received FDA clearance earlier this year. The device is a composite silicon nitride implant that combines different densities of Amedica’s proprietary medical grade silicon nitride ceramic. A solid, outer shell of nanostructured silicon nitride is manufactured around an inner porous layer, called CsC (“cancellous structured ceramic). CsC is approved for clinical use in Europe, and published clinical data from the CASCADE clinical trial have shown that it achieves spinal fusion without added bone grafts or fillers, at rates similar to those achieved by bone autograft.

“Several of our published reports have challenged the existing dogma that the surface texture of a biomaterial alone affects bone healing. Instead, we have shown that surface microchemistry also plays a critically important role in promoting bone healing. In the case of silicon nitride, we can precisely engineer both the surface nanostructure, as well as the surface microchemistry of an implant in order to stimulate bone-forming cells, speed up bone fusion, and discourage bacterial adhesion. The Valeo C+CsC with Lumen device captures these advantages by manufacturing different material densities into one smart, bioactive implant that is already optimized for spinal fusion. In contrast, competing implants made of inert metal and plastic usually require enhancement with cost-added bone fillers, surface texturing, or related gimmicks” said Dr. Sonny Bal, Chairman of Amedica. “Unlike any other biomaterial available for spinal fusion today, silicon nitride is in a class by itself,” added Dr. Bal.

The Valeo C+CsC with Lumen Interbody Fusion Device is indicated for intervertebral body fusion of the cervical spine in skeletally mature patients. Additional information about Amedica’s complete line of products can be found at www.amedica.com.

About Amedica Corporation

Amedica is focused on the development and application of medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing implants for other biomedical applications, such as wear- and corrosion-resistant hip and knee bearings, and dental implants. The Company’s manufactures its products in its ISO 13485 certified manufacturing facility. Amedica’s FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network, and OEM partnerships.

For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.

Forward-Looking Statements
This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated within this press release. A discussion of those risks and uncertainties can be found in Amedica’s Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 29, 2018, and in Amedica’s other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.

Contacts:
Amedica IR 
801-839-3502
IR@amedica.com

Global Minimally Invasive Surgical Instruments Market Outlook to 2023: A $53.1 Billion Opportunity

DUBLINAug. 20, 2018 /PRNewswire/ —

The “Minimally Invasive Surgical Instruments Market by Product, by Application, by End User, by Geography – Global Market Size, Share, Development, Growth, and Demand Forecast, 2016-2023” report has been added to ResearchAndMarkets.com’s offering.

Global minimally invasive surgical instruments market is forecasted to attain revenue of $53.1 billion by 2023.

The growth led by growing geriatric population, surge in prevalence of chronic diseases, increasing government healthcare expenditure, and growing demand for minimally invasive surgeries globally.

On the basis of product, the minimally invasive surgical instruments market has been categorized into handheld instruments, electrosurgical instruments, guiding devices, and inflation systems. Handheld instruments held a 36.4% share in 2016 in the global market, since these instruments lead to decreased strain on fingers during operative procedures, further increasing its adoption amongst surgeons globally.

The minimally invasive surgical instruments market is classified into neurosurgery, cosmetic surgery, urology, obstetrics and gynecology, ophthalmology, cardiovascular, orthopedic surgery, laparoscopy, and others, on the basis of application. Laparoscopy held the largest share in the market during the entire analysis period and the category is expected to occupy a 25.1% share by 2023, due to the rising prevalence of obesity and increasing use of laparoscopy for weight reduction (bariatric) surgeries.

On the basis of end user, the minimally invasive surgical instruments market is bifurcated into hospitals, ambulatory surgical clinics (ASCs), and research institutes. Hospitals held the largest share of more than 59.3% in 2016.

Asia-Pacific (APAC) is the fastest growing market for minimally invasive surgical instruments

APAC minimally invasive surgical instruments industry is predicted to witness the fastest growth in demand, registering 11.5% CAGR during the forecast period, owing to the increasing number of patients suffering from chronic diseases, rising geriatric population, increasing per capita income, and improving healthcare facilities in the region.

According to the United Nations Economic and Social Commission for Asia and the Pacific (UNESCAP), people aged 65 years and above constituted approximately 11.4% of the population in 2013, and the count is estimated to increase by approximately 20% by 2050. With rising population there are also chances for the population to get subjected to diseases. Thus, these rising figures, with respect to the geriatric population, are an important factor leading to the increasing demand for minimally invasive surgical instruments in the region.

The rising per capita income is likely to increase the affordability of people for expensive surgical procedures, involving minimally invasive surgical instruments. According to the World Bank, the GDP per capita of India increased from $1,345.8 in 2010 to $1,709.4 in 2016. A similar trend has been observed for other developing countries, such as Papua New Guineathe Philippines, and Indonesia, which is contributing to the growth of the APAC market.

Mergers and acquisitions are taking place at a high rate among players for a larger share

Globally, key players in the minimally invasive surgical instruments industry are acquiring other firms to gain a larger market share. For instance, in June 2017, Johnson & Johnson acquired Actelion Pharmaceuticals Ltd. (Actelion). Actelion manufactures the surgical devices. Moreover, in January 2017, the company acquired Abbott Medical Optics (AMO), a subsidiary of Abbott Laboratories. The acquisition includes ophthalmic products in three areas of patient care: cataract surgery, laser refractive surgery, and consumer eye health. These product lines joined the world- leading ACUVUE Brand Contact Lenses business, and the combined organization will operate with the name Johnson & Johnson Vision.

Some of the other major players operating in the minimally invasive surgical instruments market Applied Medical Resources Corporation, B. Braun Melsungen AG, CONMED Corporation, HOYA Corporation, Medtronic plc, Smith & Nephew plc, Stryker Corporation, Zimmer Biomet Holdings Inc. 

Key Topics Covered 

Chapter 1. Research Background
1.1 Research Objectives
1.2 Market Definition
1.3 Research Scope
1.3.1 Market Segmentation By Product
1.3.2 Market Segmentation By Application
1.3.3 Market Segmentation By End User
1.3.4 Market Segmentation By Geography
1.3.5 Analysis Period
1.3.6 Market Data Reporting Unit
1.3.6.1 Value
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown Of Primary Research Respondents
2.2.1.1 By Region
2.2.1.2 By Industry Participant
2.2.1.3 By Company Type
2.3 Market Size Estimation
2.4 Data Triangulation
2.5 Assumptions For The Study

Chapter 3. Executive Summary

Chapter 4. Introduction
4.1 Definition Of Market Segments
4.1.1 By Product
4.1.1.1 Handheld Instruments
4.1.1.1.1 Cutter Instruments
4.1.1.1.1.1 Trocars
4.1.1.1.1.2 Rasps
4.1.1.1.1.3 Others
4.1.1.1.2 Visualizing Scopes
4.1.1.1.3 Auxiliary Instruments
4.1.1.1.3.1 Staplers
4.1.1.1.3.2 Closure Devices
4.1.1.1.3.3 Cannulas
4.1.1.1.3.4 Clamps
4.1.1.1.4 Retractors
4.1.1.1.5 Dilators
4.1.1.1.6 Forceps And Spatulas
4.1.1.1.7 Graspers
4.1.1.1.8 Sutures
4.1.1.1.9 Others
4.1.1.2 Guiding Devices
4.1.1.2.1 Guiding Catheters
4.1.1.2.2 Guidewires
4.1.1.3 Inflation Systems
4.1.1.3.1 Balloons Dilators And Inflators
4.1.1.3.2 Insufflators And Insufflator Needles
4.1.1.4 Electrosurgical Instruments
4.1.1.4.1 Electrosurgical Instruments And Accessories
4.1.1.4.2 Electrosurgical Generators
4.1.1.4.3 Electrocautery Devices
4.1.2 By Application
4.1.2.1 Laparoscopy
4.1.2.2 Cardiovascular
4.1.2.3 Cosmetic Surgery
4.1.2.4 Orthopedic Surgery
4.1.2.5 Obstetrics And Gynaecology
4.1.2.6 Ophthalmology
4.1.2.7 Neurosurgery
4.1.2.8 Urology
4.1.2.9 Others
4.1.3 By End User
4.1.3.1 Hospitals
4.1.3.2 Ascs
4.1.3.3 Research Institutes
4.2 Market Dynamics
4.2.1 Drivers
4.2.1.1 Rise In Government Healthcare Expenditure
4.2.1.2 Increasing Geriatric Population And Surge In Prevalence/Incidence Of Chronic Diseases
4.2.1.3 Increasing Preference For Miss
4.2.1.4 Impact Analysis Of Drivers On Market Forecast
4.2.2 Restraints
4.2.2.1 Erratic Regulatory Environment
4.2.2.2 Improper Sterilization Procedures
4.2.2.3 Impact Analysis Of Restraints On Market Forecast
4.2.3 Opportunity
4.2.3.1 Lucrative Opportunities In Emerging Economies
4.3 Porter’S Five Forces Analysis
4.3.1 Bargaining Power Of Buyers
4.3.2 Bargaining Power Of Suppliers
4.3.3 Intensity Of Rivalry
4.3.4 Threat Of New Entrants
4.3.5 Threat Of Substitutes

Chapter 5. Global Market Size And Forecast
5.1 By Product
5.1.1 Handheld Instruments By Type
5.1.1.1 Cutter Instruments By Type
5.1.1.2 Auxiliary Instruments By Type
5.1.2 Guiding Devices By Type
5.1.3 Inflation Systems By Type
5.1.4 Electrosurgical Instruments By Type
5.2 By Application
5.3 By End User
5.4 By Region

Chapter 6. North America Market Size And Forecast
6.1 By Product
6.1.1 Handheld Instruments By Type
6.1.1.1 Cutter Instruments By Type
6.1.1.2 Auxiliary Instruments By Type
6.1.2 Guiding Devices By Type
6.1.3 Inflation Systems By Type
6.1.4 Electrosurgical Instruments By Type
6.2 By Application
6.3 By End User
6.4 By Country

Chapter 7. Europe Market Size And Forecast
7.1 By Product
7.1.1 Handheld Instruments By Type
7.1.1.1 Cutter Instruments By Type
7.1.1.2 Auxiliary Instruments By Type
7.1.2 Guiding Devices By Type
7.1.3 Inflation Systems By Type
7.1.4 Electrosurgical Instruments By Type
7.2 By Application
7.3 By End User
7.4 By Country

Chapter 8. APAC Market Size And Forecast
8.1 By Product
8.1.1 Handheld Instruments By Type
8.1.1.1 Cutter Instruments By Type
8.1.1.2 Auxiliary Instruments By Type
8.1.2 Guiding Devices By Type
8.1.3 Inflation Systems By Type
8.1.4 Electrosurgical Instruments By Type
8.2 By Application
8.3 By End User
8.4 By Country

Chapter 9. LAMEA Market Size And Forecast
9.1 By Product
9.1.1 Handheld Instruments By Type
9.1.1.1 Cutter Instruments By Type
9.1.1.2 Auxiliary Instruments By Type
9.1.2 Guiding Devices By Type
9.1.3 Inflation Systems By Type
9.1.4 Electrosurgical Instruments By Type
9.2 By Application
9.3 By End User
9.4 By Region

Chapter 10. Competitive Landscape
10.1 Market Share Analysis Of Key Players
10.2 Global Strategic Developments Of Key Players
10.2.1 Mergers And Acquisitions
10.2.2 Product Launch
10.2.3 Partnership And Collaboration
10.2.4 Facility Expansion

Chapter 11. Company Profiles
11.1 Abbott Laboratories
11.1.1 Business Overview
11.1.2 Product And Service Offerings
11.2 Applied Medical Resources Corporation
11.2.1 Business Overview
11.2.2 Product And Service Offerings
11.3 B. Braun Melsungen AG
11.3.1 Business Overview
11.3.2 Product And Service Offerings
11.4 Conmed Corporation
11.4.1 Business Overview
11.4.2 Product And Service Offerings
11.5 Hoya Corporation
11.5.1 Business Overview
11.5.2 Product And Service Offerings
11.6 Johnson & Johnson
11.6.1 Business Overview
11.6.2 Product And Service Offerings
11.7 Medtronic Plc
11.7.1 Business Overview
11.7.2 Product And Service Offerings
11.8 Smith & Nephew Plc
11.8.1 Business Overview
11.8.2 Product And Service Offerings
11.9 Stryker Corporation
11.9.1 Business Overview
11.9.2 Product And Service Offerings
11.1 Zimmer Biomet Holdings Inc.
11.10.1 Business Overview
11.10.2 Product And Service Offerings

For more information about this report visit https://www.researchandmarkets.com/research/w2x2r6/global_minimally?w=5

Media Contact:

Research and Markets 
Laura Wood, Senior Manager 
press@researchandmarkets.com 

For E.S.T Office Hours Call +1-917-300-0470 
For U.S./CAN Toll Free Call +1-800-526-8630 
For GMT Office Hours Call +353-1-416-8900 

U.S. Fax: 646-607-1907 
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com

Vericel Announces Appointment of Jonathan Hopper as Chief Medical Officer

CAMBRIDGE, Mass., Aug. 20, 2018 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the appointment of Jonathan Hopper as Chief Medical Officer.

Dr. Hopper formerly served as Senior Medical Director, Orthopedic Clinical Development for Ferring Pharmaceuticals, where he was responsible for establishing and executing the company’s strategy for Orthopedic clinical development.  Prior to joining Ferring Pharmaceuticals, he served in a number of senior medical roles including Vice President, Global Medical Director for Stryker Corporation.  Dr. Hopper also has significant medical device regulatory experience having served as a Senior Medical Officer for the UK Medicines and Healthcare products Regulatory Agency.  Dr. Hopper graduated with a M.B. Ch.B. from Birmingham University Medical School UK, is a Fellow of the Royal College of Surgeons, Edinburgh, and attained an M.B.A. at Keele University UK.

“Jon’s experience and expertise in orthopedics, wound care, and combination biologic device products are an ideal fit with Vericel’s current business and strategic focus,” said Nick Colangelo, president and chief executive officer of Vericel.  “Jon will play a key role in the execution of our life cycle management initiatives as well as our efforts to expand our product portfolio by accessing assets complementary to our existing business.”

About Vericel Corporation
Vericel is a leader in advanced cell therapies for the sports medicine and severe burn care markets.  The company markets two cell therapy products in the United States.  MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults.  Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.  For more information, please visit the company’s website at www.vcel.com.

Epicel® and MACI® are registered trademarks of Vericel Corporation. © 2018 Vericel Corporation. All rights reserved.

This document contains forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding our efforts to expand our portfolio, the commercial potential of our products and growth in revenues, intended product development, and objectives and expectations regarding our company described herein, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “anticipates,” “intends,” “estimates,” “plans,” “expects,” “we believe,” “we intend,” and similar words or phrases, or future or conditional verbs such as “will,” “would,” “should,” “potential,” “could,” “may,” or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with business development activities, competitive developments, estimating the commercial growth potential of our products and product candidates and growth in revenues and improvement in costs, market demand for our products, and our ability to supply or meet customer demand for our products. These and other significant factors are discussed in greater detail in Vericel’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”) on March 5, 2018, Quarterly Reports on Form 10-Q and other filings with the SEC. These forward-looking statements reflect management’s current views and Vericel does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.

(vcel-corp)

Global Media Contacts:
David Schull
Russo Partners LLC
David.schull@russopartnersllc.com
+1 212-845-4271 (office)
+1 858-717-2310 (mobile)

Karen Chase
Russo Partners LLC
Karen.chase@russopartnersllc.com
+1 646-942-5627 (office)
+1 917-547-0434 (mobile)

Investor Contacts:
Chad Rubin
Solebury Trout
crubin@troutgroup.com
+1 (646) 378-2947

Lee Stern
Solebury Trout
lstern@troutgroup.com
+1 (646) 378-2922